Identifying patients with HLA-related ADRs
To determine the number of patients who experienced HLA-related ADRs due
to the seven drugs included in this study, the prescription data of
participants, HLA allele information, diagnostic codes of type B ADRs
such as “toxic maculopapular eruption,” “acute generalized
exanthematous pustulosis (AGEP),” “SJS,” “TEN,” “DRESS syndrome,”
and “drug eruption” were reviewed in SUPREME®.
Because it may be inaccurate to determine patients’ drug allergies or
idiosyncratic type B ADRs based on the diagnosis code alone, we obtained
the list of patients who had type B ADRs from the Individual Case Safety
Reports database (ICSRs) (Supplementary Table 2) of the Drug Safety
Center at SNUH since January 1, 2009. The final list of patients who
experienced HLA-related ADRs was obtained by combining the data from the
SUPREME® data warehouse and ICSRs.